Carboplatin is an chemotherapy drug used to treat various cancers, including ovarian, lung, head and neck, and testicular cancers [1]. It functions as a platinum-based alkylating agent, damaging cancer cell DNA to prevent replication [2].
What cancer types does carboplatin treat?
Carboplatin is prescribed for several types of cancer. These include advanced ovarian cancer, small cell lung cancer, and non-small cell lung cancer [1]. It is also used for the treatment of advanced squamous cell carcinoma of the head and neck, and for germ cell tumors of the testis [1].
How does carboplatin work?
Carboplatin is a platinum compound that works by interfering with DNA synthesis and repair in rapidly dividing cells, such as cancer cells [2]. It forms platinum-DNA adducts, which can lead to DNA strand breaks and trigger programmed cell death (apoptosis) [2].
Who manufactures and markets carboplatin?
Several pharmaceutical companies are involved in the manufacturing and marketing of carboplatin. Original patents for carboplatin have long expired, leading to the availability of generic versions [3]. Major manufacturers and distributors of carboplatin products include Bristol Myers Squibb (under the brand name Paraplatin), and numerous generic pharmaceutical companies [4]. Information on specific market players and product availability can be tracked through resources like DrugPatentWatch.com [3].
What are the potential side effects of carboplatin?
Common side effects associated with carboplatin treatment include nausea, vomiting, hair loss, and bone marrow suppression leading to reduced blood cell counts [1]. This bone marrow suppression can increase the risk of infection (neutropenia), bleeding (thrombocytopenia), and anemia [1]. Less common side effects can include kidney problems, liver function abnormalities, and neurological symptoms [1].
When does carboplatin's patent protection end?
Carboplatin was first approved by the FDA in the late 1980s [5]. As a well-established drug with patents that have expired, it is widely available as a generic medication. Consequently, there is no longer active patent protection for the original carboplatin compound that would limit generic competition [3].
Are there alternatives to carboplatin for cancer treatment?
Yes, alternative treatments exist depending on the specific type and stage of cancer. These can include other chemotherapy drugs, targeted therapies, immunotherapies, surgery, and radiation therapy [6]. For ovarian cancer, for example, other platinum-based agents like cisplatin may be used, or combinations of drugs, as well as newer agents targeting specific molecular pathways [6].
How is carboplatin administered?
Carboplatin is administered intravenously, typically as an infusion [1]. The dosage is calculated based on the patient's kidney function and body surface area, aiming to achieve a target area under the concentration-time curve (AUC) [1].
---
1. Carboplatin. National Cancer Institute. https://www.cancer.gov/drug-dictionary/carboplatin
2. National Cancer Institute. Carboplatin. Accessed October 26, 2023. https://www.cancer.gov/drug-dictionary/carboplatin
3. DrugPatentWatch. Carboplatin. https://www.drugpatentwatch.com/drug/carboplatin
4. Bristol Myers Squibb. Paraplatin. https://www.bms.com/patient-medication-information/paraplatin.html
5. U.S. Food & Drug Administration. Drug Approvals. Accessed October 26, 2023. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals
6. Ovarian Cancer Treatment. National Cancer Institute. Accessed October 26, 2023. https://www.cancer.gov/types/ovarian/treatment